1 / 41

Hypertension and nephropathy in diabetes

Hypertension and nephropathy in diabetes. R Ajjan Senior Lecturer and Honorary Consultant Diabetes and Endocrinology The LIGHT Laboratories University of Leeds Leeds General Infirmary. Case 1. A 27 year old with T1DM for 14 years. Complications Background retinopathy Current treatment

ernie
Download Presentation

Hypertension and nephropathy in diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hypertension and nephropathy in diabetes R Ajjan Senior Lecturer and Honorary Consultant Diabetes and Endocrinology The LIGHT Laboratories University of Leeds Leeds General Infirmary

  2. Case 1 A 27 year old with T1DM for 14 years. • Complications • Background retinopathy • Current treatment • Novomix 30: 28 and 16 units • Recent results • HbA1c 7.8% • U&Es • Na 140 mmol/l, K 3.7 mmol/l, Urea 3.4 mmol/l, Creatinine 77 mmol/l • Lipids • TC 4.9 mmol/l, TG 1.7 mmol/l • ACR 4.1 and 3.9 (N<2.5) checked twice in 2 months

  3. Discussion points (Case 1) • Patient has microalbuminuria together with at least one other microvascular complication (discuss treatment ARB/ACEI). • Needs tightening of glycaemic control to prevent further deterioration of microvascular complications (UKPDS) • Increased CV risk; need to consider a statin (JBS)

  4. -16 P=0.052 MI Retinopathy Cataract extraction Microvascular endpoint Albuminuria at 12 years Any diabetes related endpoint -21 P=0.015 -24 P=0.046 -25 P=0.009 -34 P=0.00005 -12 P=0.029 0 -10 -20 -30 -40 -50 % Reduction in Risk Lowering HbA1C Reduces Risk of Complications In intensively-treated patients, HbA1C was 0.9% lower compared with conventionally treated patients UK Prospective Diabetes Study (UKPDS) Group (33). Lancet 1998; 352 (Sept. 12): 837–853.

  5. Miettinen H, et al. Stroke 1996; 27:2033–2039.

  6. Microalbuminuria and CV outcome(DM and non-DM individuals) • MA is associated with CAC • MA is associated with carotid and femoral artery stenosis • MA is associated with LVH/LV dysfunction and ECG abnormalities • MA and MI • a marker of silent MI (DM and non-DM) • related to MI size • a predictor of 1 yr mortality post MI • MA is a predictor of ischemic stroke Liu, J Am Coll Cardiol 2003, 41:2022 Earle, Diabetologia 1996, 39:854 Diercks, Eur Heart J 2000, 21;1922 Berton J Hypertens 1998, 16:515 Spoelstra-de Man, Diab Care 2001, 24:2097 Beamer, Arch Neurol 1999, 56: 699 Kramer, Hypertension 2005, 46:38

  7. CV mortality in relation to MA&ECG(>7000 subjects) Aged 28-75 Diercks, J Am Coll Cardiol 2002, 40:1401

  8. Case 2 • 18 year old male with T1DM for 2 years. • No known complications • Results • BP 160/90 • HbA1c 8.1% • Na 136, K 4.1, Creatinine 95, Urea 7.5 • Chol 6.7, TG 5.6 • Urine ACR 495 (N <2.5) • Urine MC&S negative

  9. Learning points (Case 2) • Severe microalbuminuria in the absence of other microvascular disease is unlikely to be diabetes-related and needs to be fully investigated (this patient had glomerulonephritis with nephrotic syndrome) • Raised TC should be discussed (? Secondary to nephrotic syndrome)

  10. Prevention of DM nephropathy Yearly screen using ACR. Rule out microalbuminuria secondary to other causes. • Exercise. • Poor glycemic control. • Poorly controlled Hypertension. • UTI. • Pregnancy. • Fever. • Haematuria. • CCF. If positive, repeat twice (in 3 months). If 2 of 3 positive, initiate treatment.

  11. Case 3 • A 31 year old T1DM patient for 5 years. He is complaining of episodes of palpitation and sweating. Also, dizziness on standing. • Treatment • Novorapid 12 units tds • Lantus 24 units od • Results • Weight 70, BMI 24 • BP L: 195/105; S 170/95 • HbA1c: 7.1% • U&Es • Na 134 mmol/L, K 4.3 mmol/L, U 4.3 mmol/L, Creatinine 82 mmol/L • Lipids • TC 3.9, TG 2.1

  12. Learning points (Case 3) • Severe hypertension in a young patient, particularly in the presence of symptoms, should be fully investigated. • This patient had a pheochromocytoma

  13. Secondary causes of HBP • Endocrine • Pheochromocytoma • Conn’s • Acromegaly • Cushing’s • Non-endocrine • Renal artery stenosis • Coarctation of the aorta

  14. Case 4 • 57 year old T1DM for more than 30 years. • Complications • Microalbuminuria • Hypertension • Hyperlipidaemia • Treatment • Glargine and novorapid • Ramipril 10 mg • BFZ 2.5 mg • Atorvastatin 10mg • Aspirin 75 mg • Results • Weight 65 (BMI 24), HbA1c 7.3%, BP 155/86 • Na 137, K 4.9, Urea 6.1, Creatinine 102 • TC 4.9, LDL 2.9, TG 1.3

  15. Learning points (Case 4) • Recognise that HBP is the most important point to focus on (discuss antihypertensive treatment options). • Due to multiple risk factors, a more aggressive approach with lipid lowering agents is probably warranted.

  16. Impact of Blood Pressure Reduction on Mortality in Diabetes Mortality endpoints are: UK Prospective Diabetes Study (UKPDS) – “diabetes related deaths” Hypertension Optimal Treatment (HOT) Study – “cardiovascular deaths” in diabetics Turner RC, et al. BMJ. 1998;317:703-713. Hansson L, et al. Lancet. 1998;351:1755–1762.

  17. Diabetes: Tight Glucose vs Tight BP Control and CV Outcomes in UKPDS DM Deaths Microvascular Complications Stroke Any Diabetic Endpoint 0 5% 10% -10 12% -20 24% % Reduction In Relative Risk * 32% 32% -30 * 37% * *P <0.05 compared to tight glucose control -40 44% Tight Glucose Control (Goal <6.0 mmol/l or 108 mg/dL) Tight BP Control (Average 144/82 mmHg) * -50 Bakris GL, et al. Am J Kidney Dis.2000;36(3):646-661.

  18. Case 5 • 47 year old with insulin treated T2DM and 12 months history of erectile dysfunction • Results • HbA1c 7.3% • U&Es N • Chol 5.8 mmol/l, TG 2.3 mmol/l • ALT 160, AP 397, Bili 31 • Testosterone 5 (low), FSH 1.1 (low), LH 0.8 (low) • Prolactin 233 • Would you give a statin? What would you do?

  19. Learning points (case 5) • Discuss erectile dysfunction in DM • Recognise high lipids. • Recognise abnormal LFTs (? Statins CI): discuss when to investigate abnormal LFTs in DM patients. • Unifying diagnosis (haemachromatosis)

  20. Classification of Diabetes (1)

  21. Classification of Diabetes (2) • Latent autoimmune diabetes in adults (LADA); Type I. • Maturity onset DM of the young (MODY); Type II. • Gestational diabetes. • Secondary: pancreatic destruction (pancreatitis, cystic fibrosis), Acromegaly, Cushing’s syndrome, Haemochromatosis.

  22. Case 6 38 year old lady diagnosed with T1DM for 15 years. Also suffers from a bipolar disorder. Treatment Levemir 16 and 12 units Novorapid (CHO counting 1:10) Lithium Complaining of tiredness Results HbA1c 7.8% FBC Hb 11.1, MCV 100, WBC 4.6, Plat 221. U&Es Na 138 mmol/l, K 4.3 mmol/l, Cr 87 mmol/l, Urea 5.1 mmol/l. Lipids TC 6.8 mmol/l, TG 1.6 mmol/l (4.8 and 1.4 respectively, 8 months ago)

  23. Learning points (case 6) • A big change in TC over 8 months is suspicious (need to think about secondary hypercholesterolaemia) • Notice raised MCV • Dx hypothyroidism

  24. Case 7 • 27 year old lady with T1DM for 12 years • No documented complications, no FH • On qds insulin; feels her diabetes is well controlled • Bloods HbA1c 6.6% TC 5.1 (HDL 2.2; LDL 2.9, TG 1.1) U&Es (normal); alb/creatinine ratio (normal)

  25. Learning points (case 7) • A woman in a child bearing age. • Minor rise in TC • No other complications/good DM control. • The immediate risk is negligible and therefore medical treatment is probably not advised.

  26. JBS guidelines • TC <4.0 and LDL<2.0 or 25% reduction in TC and 30% reduction in LDL. • TG<1.7 and HDL>1.0 are preferred (but not targets) • For audit purposes TC<5 and LDL<3!

  27. Who should be given statins (JBS) • All diabetics above the age of 40 (T1DM and T2DM) • Individuals between 18-39 who have diabetes and: • Significant retinopathy • Nephropathy • HbA1c>9.0% • HBP requiring treatment • TC>6.0 • FH of IHD • Presence of the metabolic syndrome (central obesity, TG, HDL)

  28. Case 8 May 2004 • Weight 63 • TC 5.2, LDL 3.6, TG 2.6 • HbA1c 8.4 • Na 137, K 4.2, Cr 61, U 4.1 November 2004 • Weight 52 • TC 4.0, LDL 2.8, TG 1.4 • HbA1c 6.1 • Na 137, K 3.9, Cr 52, U 3.2 • Calcium 1.94 28 year old lady with T1DM. Found to have raised cholesterol and was given dietary advice. Complaining of tiredness, frequent hypos and pins & needles in the hands.

  29. Learning points (case 8) • Weight loss and hypos in T1DM should be investigated. • DD • Poor control • Coeliac disease (Dx in this case): note low calcium • Addison’s • Hyperthyroidism • General causes of weight loss (including malignancy)

  30. Case 9 • 37 year old male T1DM for 15 years, HBP for 6 years. • Current Tx • Lantus and Novorapid • Ramipril 10 mg od (for 6 years) • Feeling very tired and having frequent hypos. • Results • W 58 kg • BP 90/55 • Na 135, K 5.7, Creatinine 64, Urea 3.1 • What would you do?

  31. Learning points (case 9) • Weight loss and hypos in T1DM should be investigated. • DD • Poor control • Coeliac disease • Addison’s (Dx in this case) • Hyperthyroidism • General causes of weight loss (including malignancy)

  32. Case 10 • A 24 year old lady with T1DM for 16 years. • FH includes T2DM diabetes in her father and brother diagnosed at the age of 32 and 22 respectively. • Treatment • Novomix 30: 4 units twice a day • Results • Weight 59 kg, BMI 22 • HbA1c 5.4% • U&Es normal • ACR 1.1 • TC 3.4, TG 1.1

  33. Learning points (case 10) • Excellent control despite small doses of insulin. • FH of T2DM • Need to question the Dx of T1DM • Patient had MODY

  34. MODY Hattersley, Endocrinology 2006; 147: 2657

  35. Case 11 • A 38 year old lady with T1DM for 9 years and hypothyroidism for 7 years. • Complaining of loss of sensation in the feet and problems with her balance, particularly when walking in the dark. • No retinopathy or nephropathy • Treatment • Novomix 30: 42 and 28 units • Simvastatin 40 mg od • L-thyroxine 100 mcg od • Results • HbA1c 6.8% • U&Es normal • Lipids TC 3.8, TG 1.2 • FT4 19 pmol/l, TSH 1.9 mIU/l

  36. Learning points (case 11) • Recognise that it is unusual to have diabetic neuropathy in the absence of other micorvascular complications. • This should prompt full investigations. • Patient already has two autoimmune conditions. • Need to rule out PA (dx here)

  37. Treatment options to prevent/treat complications in DM • CVD • Good glucose control • Metformin • Glitazones • ACEI • ARB • Statins • ? Fibrates • ? Omega-3 • ? aspirin • Nephropathy • Good glucose control • ACEI • ARB • Neuropathy • Good glucose control • Simple analgesics • Tricyclic antidepressants • Gabapentin • Pregabalin • Retinopathy • Good glucose control • Laser treatment • ?others Diabetes UK: Within the next 5 years, the possible number of drug combinations in T2DM may be > 4500

  38. THANK YOU

More Related